Navigation Links
Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference --
Date:10/30/2008

Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter 2008 financial results before the market opens on Monday, November 3, 2008.

BERKELEY, Calif. (Business Wire EON) October 30, 2008 -- The company also plans to have a corporate overview presentation at the Oppenheimer 19th Annual Healthcare Conference in New York City on November 3, 2008 at 11:20 a.m. EST (8:20 a.m. PST). Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will present at this conference. To access the live audio webcast and the subsequent archived audio recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/events.cfm.

About Dynavax

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of infectious diseases, respiratory diseases and cancer. The company's novel Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary immunostimulatory sequences (ISS), which are short DNA sequences that stimulate the innate immune response. Dynavax's clinical product candidates include: HEPLISAVTM, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for hepatitis B; and therapies for cancer and hepatitis C funded by Symphony Dynamo, Inc. The company's preclinical pipeline includes an asthma and COPD drug candidate partnered with AstraZeneca and a Universal Flu vaccine. For more information visit www.dynavax.com.

Read the full story at http://www.prweb.com/releases/healthcare_conference/report_third/prweb1551714.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences
2. Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
3. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
4. Dynavax to Present at Bear Stearns 20th Annual Healthcare Conference
5. Almost Family, Inc. to Report Third Quarter 2008 Financial Results
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Claimsnet.com Reports Third Quarter 2008 Results
10. Cancer requires support from immune system to develop, UT Southwestern researchers report
11. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Dynavax to Report Third Quarter 2008 Financial Results :  -- To Present at Oppenheimer's Healthcare Conference -- 
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: